07 jun: Afnotering af Arkil Holding A/S
11 jun: Indre værdi af SmallCap Danmark A/S er opgjort til 10,6 kr. pr. a..
11-06-2019 02:00:00

Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)

Press release – No. 14 / 2019

 

Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)

  • The pivotal Phase 3 trial demonstrates that a single dose of dasiglucagon rapidly increases blood glucose levels in type 1 diabetes patients with low plasma glucose

     

  • The median time to plasma glucose recovery was 10 min following dasiglucagon injection, with 99% of patients having recovered within 15 minutes

 

Copenhagen, June 11, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, presented elaborated results from the pivotal Phase 3 study of dasiglucagon as treatment for severe hypoglycemia at the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California. Abstract No. 286-OR was presented on Monday, June 10 at 4:00 PM Pacific.

Dasiglucagon has the potential to offer millions of people living with diabetes the fastest and most effective rescue treatment for severe hypoglycemia. Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand. It is in development in the ready-to-use HypoPal® rescue pen for easy, fast and effective treatment of severe hypoglycemia.

The results were shared as an oral presentation: Phase 3 Results for dasiglucagon as a fast and effective treatment for severe hypoglycemia, by Professor, Dr. Thomas R. Pieber, Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology. The study confirmed the efficacy and safety of dasiglucagon in the treatment of hypoglycemia in type 1 diabetes subjects. The data demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus with insulin-induced hypoglycemia. Additionally, the study compared the glycemic response and tolerability observed after administration of dasiglucagon with that of GlucaGen®.

“The Phase 3 data in this multi-center study confirmed dasiglucagon as a potential emergency glucagon treatment with a fast recovery profile. Recovery was observed within 10 minutes for almost two-thirds of the subjects,” commented Professor, Dr. Thomas R. Pieber, Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology.

“The pivotal Phase 3 data established the fast onset of action by dasiglucagon, which we believe is of major importance when treating severe hypoglycemia,” said Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma. “We believe that people living with insulin-dependent diabetes should be offered new alternatives to treating severe hypoglycemia, and we are excited about the opportunity for the dasiglucagon HypoPal® rescue pen.”

 

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

 

Dasiglucagon (glucagon analog stable in liquid formulation) for use in other indications

Dasiglucagon is a Zealand-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of type 1 diabetes with a next-generation artificial pancreas, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).

About t

ype 1 diabetes and hypoglycemia

People with type 1 diabetes suffer from insulin deficiency and inappropriate glucagon secretion. Both hormones are essential to ensure stable and healthy blood glucose levels. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.

Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy. Severe hypoglycemia occurs most frequently in people with type 1 diabetes due to injecting insulin multiple times daily. It is the biggest concern for insulin-dependent patients and the most feared complication of diabetes treatment. The condition is characterized by confusion, seizures, and often loss of consciousness that can result in death if left untreated.

When a patient has a hypoglycemic event, a second person must assist in treatment. Currently marketed formulations of glucagon for the treatment of severe hypoglycemia require mixing first by the person assisting to treat and then immediate administration due to poor drug stability. Dasiglucagon is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

 

Attachment

Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg

Relateret indhold
09 sep - 
Briter skruer ned for sats på kursfald til Pandora - og..
06 sep - 
Fredagens aktier: Vestas med flere sikrede netop spinke..
06 sep - 
Zealand Pharma/Kempen: Løfter kursmål med 60 kr. til 22..
Relateret debat
13 sep - 
+1,12% - Endnu en dejlig dag på kontoret :-)
13 sep - 
Det kan ikke vare længe før et par at de størrer børshu..
13 sep - 
Py ha, det må ikke være sjovt at være short i Zealand, ..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
10 sep
ZEAL
Der er langt ned til 133, men ingen umulighed.
1

Lars Christensen Verden - Episode 25: Markederne og verdens elendige tilstand

11-09-2019 23:11:20
Hvis ugens gæst, seniorstrateg Andreas Steno fra Nordea Markets, og Lars Christensen havde haft sæde i Federal Reserves pengepolitiske komité, havde verden set anderledes ud - i hvert fald pengepolitikken. USA's ledende pengepolitiske rente havde f.eks. fået et nøk mere nedad tilbage i juli, navnlig i lyset af den tiltagende recessionsrisiko, lave inflation, og  at den såkaldte rentekurve blev neg..

Danske Bank i største hop i seks år: Øger markedsværdi med 7 mia. kr.

09-09-2019 17:10:29
Pilen pegede generelt ned for det danske aktiemarked mandag, men Danske Bank trodsede stemningen og bankede op med hele 9,1 pct. til 99,48 kr. Det var den største stigning i omtrent seks år, hvilket øgede markedsværdien med 7,1 mia. kr. til samlet 85,8 mia. kr.Mandag kom det frem, at analytikere fra Bloomberg Intelligence mener, at markedet er alt for pessimistisk, i forhold til hvor stor en bøde ..

Aktier/åbning: Maersk Drilling i front for lysegrønt C25

09-09-2019 09:17:42
Det danske aktiemarked er mandag åbnet let positivt efter en pæne stigning til blandt andet Maersk Drilling, der bliver løftet af stigende oliepriser.Efter godt 10 minutters handel ligger C25-indekset 0,1 pct. højere i 1157,76 og indekset har dermed sat kurs mod sjette dag i træk med fremgang.Der har generelt været små plusser at finde på de asiatiske markeder, og futures har op til åbningen også ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 162,90 1,1% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 162,90 1,1% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. september 2019 18:15:46
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190829.2 - EUROWEB2 - 2019-09-15 18:15:46 - 2019-09-15 18:15:46 - 1 - Website: OKAY